Simultaneous testing for detection of infectious pathogens that cause similar symptoms (e.g., acute respiratory infections) is invaluable for patient treatment, outbreak prevention, and efficient use of antibiotic and antiviral agents. In addition, such testing may provide information regarding possible coinfections or induced secondary infections, such as virally induced bacterial infections. Furthermore, in many cases, detection of a pathogen requires more than genus/species-level resolution, since harmful agents (e.g., avian influenza virus) are grouped with other, relatively benign common agents, and for every pathogen, finer resolution is useful to allow tracking of the location and nature of mutations leading to strain variations. In this study, a previously developed resequencing microarray that has been demonstrated to have these capabilities was further developed to provide individual detection sensitivity ranging from 10 1 to 10 3 genomic copies for more than 26 respiratory pathogens while still retaining the ability to detect and differentiate between close genetic neighbors. In addition, the study demonstrated that this system allows unambiguous and reproducible sequence-based strain identification of the mixed pathogens. Successful proof-of-concept experiments using clinical specimens show that this approach is potentially very useful for both diagnostics and epidemic surveillance.
Accurate and rapid identification of infectious pathogens that cause similar symptoms, such as acute respiratory infections (ARIs), can be a critical factor in the successful treatment of the illness, outbreak control measures, and the efficient use of precious antibiotics and antiviral drugs (30, 40) . Simultaneous testing for all possible pathogens is an efficient means to obtain a conclusive result. In addition, assaying for all potential pathogens may yield information regarding possible coinfections or induced secondary infections (e.g., virally induced bacterial infections). Currently, many promising approaches using reverse transcription-PCR (RT-PCR)/PCR amplification strategies as multiplexed approaches for testing several organisms are being developed (1, 2, 4-10, 14-16, 22, 23, 25, 28, 36, 37, 41, 42) . While these approaches are versatile, additional strategies must be implemented to ensure good specificity for the assay. In cases where closely related organisms can have very different clinical consequences and epidemiological patterns (e.g., Bordetella pertussis versus Bordetella parapertussis), discrimination to the species, serotype/subtype, or even strain level is required to reduce the incidence of false positives (22) . Influenza virus detection is a case where serotype/subtype discrimination, at a minimum, is required. In addition, strain-level information can be used to quickly discern the effectiveness of vaccines and make proper recommendations for appropriate outbreak control measures. Furthermore, the sequence information of new circulating human isolates and possible zoonotic strains [e.g., avian influenza virus (H5N1)] that are detected will be of immediate and obvious value for potential vaccine candidate prediction.
A resequencing microarray approach is advantageous in addressing these issues. This platform can maintain specificity, provide information on mutation hot spots and strain variants, and monitor all these aspects in a few long sections of DNA/ RNA sequence. Our previous work has demonstrated the potential of short-oligonucleotide resequencing arrays to simultaneously provide both species-level and strain-level identification of amplicons from respiratory pathogens (19, 39) . This approach has been used to efficiently and simultaneously detect, type, and genetically characterize geographically diverse influenza viruses (39) . The sequences produced by the resequencing arrays were identical to the results from conventional sequencing methods with the exception of ambiguous base calls (NЈs) (19, 39) . The microarray results were analyzed using a new approach that compared the sequence of bases determined to all previously sequenced results. Thus, it is possible both to correctly identify the organism and to determine the difference in sequence between the organism detected and previously sequenced organisms (21) . In the initial studies, random amplification methods were used as the enrichment method to provide the sensitivity necessary for this potential diagnostic assay. This broadly targeted enrichment method was initially selected for its potential benefits in reducing biased amplification of one organism over another and in amplifying mutated organisms that a more specific amplification method might miss.
While the initial results using random amplification and a resequencing microarray are very promising, several issues must be addressed before this technology can be considered ready for use in a surveillance or diagnostic application. Specifically, the generic amplification methods, which performed well with analytic test samples, did not consistently detect organisms in complex clinical samples with lower titers. In addition, the analysis method was complex and time-consuming and required the expertise of highly trained individuals. In this study, in order to overcome the sensitivity issue related to random target amplification, we developed an alternate amplification strategy, optimized multiplex PCR, which provides greater sensitivity for clinical samples while still being capable of identifying the presence of close genetic neighbors (e.g., various adenovirus serotypes). Furthermore, to demonstrate that this approach is effective for the simultaneous detection of multiple pathogens, we tested the system's capability for detecting mixed multiple pathogens in analytic control samples and complex backgrounds (mimicking real-world situations). The results demonstrate that this approach allows unambiguous and reproducible sequence-based strain identification of the mixed pathogens. Further testing, using clinical specimens (throat swabs) obtained from patients presenting febrile illness, showed that we can achieve high species-level concordance with standard reference assays while at the same time producing correct species and strain-level identification via direct sequence reads in an assay time of around 8.5 h. These results show that this approach is amenable to the development of a robust microarray-based platform that offers comprehensive coverage of the significant respiratory pathogens for both diagnostic and surveillance purposes.
MATERIALS AND METHODS
RPM v.1 chip design. The design of respiratory pathogen microarray, version 1 (RPM v.1), chips includes 57 target genes comprising partial sequences from the genes containing the diagnostic regions of each pathogen (i.e., E1A, hexon, and fiber for human adenoviruses [HAdV's] ; the hemagglutinin (HA), neuraminidase (NA), and matrix genes for influenza A viruses). This allows resequencing of 29.7 kb of sequences from 26 respiratory pathogens and biowarfare agents (Table 1) known to cause "flu-like" symptoms at early stages of infection, as described in detail in a previous report (19) . Briefly, RPM v.1 arrays consist of prototype sequences (ProSeqs), which are a collection of probes chosen to represent portions of the genomic DNA/RNA of a targeted organism. ProSeqs consist of sequential 25-mer perfect-match probes, each in its own probe set, representing each base of the prototype sequence chosen from the genome of the target organism. For each perfect-match probe, the remainder of the probe set consists of three mismatch probes representing the three possible single-nucleotide polymorphisms of the center position. Thus, hybridization to a series of probe sets provides redundant presence/absence information for the organism while also revealing strain-specific single-nucleotide polymorphisms relative to the sequence chosen.
Prototype strains. All control and field strains used to test the sensitivity and specificity of RPM v.1 and their sources are listed in Table 1 .
Clinical samples. Archived throat swabs were collected from patients with symptoms of ARI at various military recruit training centers, at U.S.-Mexico border sites, and on deployed naval ships from 1999 to 2005. These were immediately placed in 2-ml cryogenic vials containing 1.5 ml of viral transport medium (MICROTEST, Multi-Microbe Media; Remel Inc., Lenexa, KS), frozen, and stored at or below Ϫ80°C to maintain the viral particles during transport. Samples were then shipped to the Naval Health Research Center (NHRC; San Diego, CA), a molecular diagnostics laboratory certified by the College of American Pathologists (CAP), where they were thawed, aliquoted, and tested for human adenoviruses and influenza virus using CAP-approved diagnostic RT-PCR/PCR and culture tests. Frozen aliquots were then submitted for microarraybased detection in a blinded fashion. Informed consent was obtained from all participants after the nature and possible consequences of the studies were explained.
These samples were collected, and this research has been conducted, in compliance with all applicable federal and international regulations governing the protection of human subjects in research, under Naval Health Research Center (NHRC) work unit number 60501, Department of Defense protocols NHRC.1999.0002.31271 and NHRC.2003.0002 .
Chip processing protocol. Figure 1 is a schematic diagram of the processing protocol. The details of each processing step are described below.
Nucleic acid extraction. Nucleic acids were extracted from clinical samples using either the MasterPure DNA purification kit (Epicentre Technologies, Madison, WI), omitting RNase digestion, or the MagNA Pure Compact nucleic acid isolation kit I (Roche Applied Science, Indianapolis, IN) according to the manufacturer's recommended protocols.
Internal controls. Two Arabidopsis thaliana plant genes, corresponding to NAC1 and triosphosphate isomerase (TIM), were chosen as internal controls for RT and PCRs, since they would be unlikely to occur naturally in clinical samples. Two plasmids, pSP64poly(A)-NAC1 and pSP64poly(A)-TIM, containing ϳ500 bp of the two genes, were kindly provided by Norman H. Lee of The Institute for Genome Research (Rockville, MD) (38) . NAC1 was amplified by PCR with SP6 and M13R primers, and the PCR products were purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA). To generate RNA from pSP64poly(A)-TIM, the plasmids were linearized with EcoRI and in vitro transcribed from the SP6 promoter using the MEGAscript high-yield transciption kit (Ambion, Austin, TX). Sixty femtograms each of NAC1 and TIM were used as internal controls for checking the amplification efficiency and the presence of inhibitors in the specimens.
Primer design and multiplex RT-PCR amplification. The gene-specific primer pairs for all targets on the RPM v.1 chip (listed in Table S1 in the supplemental material) were designed to meet the minimum amplification efficiency requirement (to provide a detection sensitivity of 10 1 to 10 3 genome copies per target) for multiplex PCR. All primers were designed to have similar annealing temperatures and were checked to ensure uniqueness using a full search of the GenBank database with the BLAST program for known sequences. All primers were checked for potential hybridization to other primers in order to reduce the potential of primer-dimer formation. In addition, we adapted a method developed by Shuber et al. and Brownie et al. (3, 32) to further suppress primer-dimer formation by adding a linker sequence of 22 bp (primer L) to the 5Ј ends of primers used in this study. To further minimize the possibility of intraprimer interactions, the primers were divided into two independent reactions to simplify primer design and optimization. Fine-tuning adjustments to both mixtures (replacing primers that amplified poorly with new ones) were carried out to ensure that all target genes from the 26 targeted pathogens (West Nile virus is included on the array but not in this amplification scheme) would amplify sufficiently to generate detectable hybridization.
RT reactions were performed in 20-l volumes containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 500 M each dATP, dCTP, dGTP, and dTTP, 40 U of RNaseOUT, 10 mM dithiothreitol, 2 M primer LN, 200 U of Superscript III (Invitrogen Life Technologies, Carlsbad, CA), 60 fg of each of the two internal controls (NAC1 and TIM), and 5 to 8 l of the extracted clinical specimen or laboratory control. Reactions were carried out in a Peltier thermal cycler-PTC240 DNA Engine Tetrad 2 (MJ Research Inc., Reno, NV) using the manufacturer's recommended protocol.
The RT reaction products were split up into two 10-l volumes to be subjected to two different multiplex PCRs. Primer mix A contains 19 primer pairs and amplifies 18 gene targets from three different influenza A viruses, one influenza B virus, three HAdV serotypes, and one internal control (TIM). Primer mix B contains 38 primer pairs and amplifies the remaining 37 gene targets and the other internal control (NAC1). PCRs were performed in 50-l volumes containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2 mM MgCl 2 , 400 M each dATP, dCTP, dGTP, and dUTP, 1 U of uracil-DNA glycosylase, heat-labile (USB Corporation, Cleveland, OH), 2 M primer L, 40 nM each primer from mix A or 50 nM each primer from mix B, 10 U of Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA), and 10 l of the RT product. The amplification reaction was carried out in a Peltier thermal cycler-PTC240 DNA Engine Tetrad 2 (MJ Research Inc., Reno, NV) with initial incubation at 25°C for 10 min; preliminary denaturation at 94°C for 3 min, followed by 5 cycles of 94°C for 30 s, 50°C for 90 s, and 72°C for 120 s; 35 cycles of 94°C for 30 s and 64°C for 120 s; and a final extension at 72°C for 5 min. The amplified products from the two PCRs were combined into a single volume and subjected to purification and processing prior to hybridization to the RPM v.1 chips (see below).
Microarray hybridization and processing. Microarray hybridization and processing were carried out according to the manufacturer's recommended protocol (Affymetrix Inc., Santa Clara, CA) using a GeneChip resequencing assay kit (Affymetrix Inc.) with the following modification. Purified PCR products were fragmented for 5 min and then labeled for 30 min. Hybridization was carried out at 45°C for 2 h. The images were scanned and processed as previously described to produce FASTA output files (19) .
Automatic pathogen identification algorithm. A new software program, the computer-implemented biological sequence-based identifier system, version 2 (CIBSI 2.0), was used to automate the pathogen identification process for the RPM v.1 array. CIBSI 2.0 incorporates the general concept of the resequencing pathogen identification (REPI) program (19) and in addition analyzes the result and makes decisions, steps that were previously carried out manually. A broader discussion of this protocol, including an improved REPI algorithm, is described in detail elsewhere (21) .
Quantification of pathogens. For sensitivity assessments, real-time PCR assays were conducted on an iCycler or MyiQ instrument (Bio-Rad Laboratories, Hercules, CA) to determine the number of pathogen genomes in each sample. The findings for the samples were compared to those for 10-fold serial dilutions of prototype genomic DNA templates with known copy numbers (10 1 to 10 6 copies) by using specific primers and RT-PCR/PCR conditions as previously described in the literature (see Table S2 in the supplemental material) (11, 17, 24, 34, 35) . The genomic copy number of the pathogen was calculated by measuring the DNA/ RNA concentration from purified genomic DNA/RNA and using conversion factors as follows. Molecular mass (y) is calculated as the number of base pairs ϫ 660 Da (average molecular mass for 1 bp at 330 Da for each nucleotide). Grams of DNA per genome copy is calculated as y daltons ϫ 1.67 ϫ 10 Ϫ24 g (e.g., a single adenovirus genome of ϳ35 kb has a molecular mass of 2.31 ϫ 10 7 Da, which is equivalent to 3.86 ϫ 10 Ϫ17 g; 1 ng of purified adenovirus genomic DNA is equivalent to 2.6 ϫ 10 7 genome copies) (31) . Real-time PCRs were carried out in 25-l reaction volumes containing 2.5 l FastStart reaction mix SYBR Green I (Roche Applied Science, Indianapolis, IN), 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl 2 , 200 M each dATP, dTTP, dGTP, and dCTP, 200 nM primers, and genomic DNA (1 to 4 l of clinical specimen or DNA extracts).
RESULTS
Analytical sensitivity and specificity of the RPM v.1 assay. A split multiplex PCR protocol that divides the sample to amplify the 57 gene targets on the RPM v.1 chip was developed to VOL. 45, 2007 SIMULTANEOUS TESTING FOR OVER 20 RESPIRATORY PATHOGENS 445 overcome the sensitivity issues related to random target amplification. The specificity of this assay was confirmed using various prototype strains and clinical samples. The results showed only noninterfering hybridization, by which we mean hybridization of nontarget amplicons, resulting in base calls occurring for only a few target probe sets, which was insufficient to cause an incorrect identification. No significant crosshybridization occurred between any targets. The largest number of base calls generated from noninterfering hybridization was observed on HAdV hexon genes when the different serotypes were used as the template. But the sequences generated still did not cause misidentification. This is due to the fact that sequence information produced on the microarray can distinguish noninterfering hybridization from hybridization of the intended target. The analytical sensitivity of the RPM v.1 assay was then evaluated using serial 10-fold dilutions of the nucleic acid templates of the prototype strains. Table 1 shows the lowest detectable dilution of each pathogen. The results revealed an individual sensitivity that ranged from 10 1 to 10 3 genomic copies per reaction for the prototype strains, which is comparable to the sensitivity of standard multiplex RT-PCR/PCR methods. The genome copy number should not be equated to the CFU or PFU but was used so that comparisons could be made between pathogens from different sources. The number of genome copies represented by the CFU or PFU of a patient sample can vary from one to several orders of magnitude greater for various respiratory pathogens. The capability of RPM v.1 to identify and discriminate between near genetic neighbors is dependent not only on the capabilities of the microarray but also on the amplification strategy. The capability of RPM v.1 was first demonstrated with random amplification protocols and has been reproduced with this multiplexed amplification protocol. This assay distinguished between 11 different serotypes of ARI-associated HAdV's and also differentiated four different strains of HAdV-4, three strains of HAdV-7, and two strains of HAdV-3. These results demonstrated that the newly developed multiplexed amplification would detect a range of variants comparably to random amplification methods ( Table 2) .
Simultaneous detection and differentiation of respiratory pathogens. In this study, we further assess the ability of the RPM v.1 assay to identify multiple pathogens simultaneously, i.e., coinfections, by the preparation of various combinations of pathogen templates (see Tables S3 and S4 in the supplemental material). Serial dilutions of nucleic acid templates were used to evaluate the detection sensitivity and specificity for multiple pathogens. Initially, samples containing 10 3 to 10 6 genome copies per reaction of four pathogens-HAdV-4, Streptococcus pyogenes, Mycoplasma pneumoniae, and Yersinia pestis-were prepared. Tests using the RPM v.1 assay demonstrated reproducible sequence-based identification of all four pathogens, even at the lowest concentration of 10 3 genomic copies per target per reaction (see Table S3 in the supplemental material). In addition to tests in which targets are present at the same concentration, experiments were carried out diluting only one of two pathogens, representing a situation possible for many clinical specimens, especially those identified as coinfections. Using the combination of HAdV-4 (10 5 genome copies) 
FIG. 1. Schematic of the processing protocol.
Clinical samples (nasal swab or nasal wash specimens) were collected from patients presenting ARI symptoms. Nucleic acids were extracted from these samples, followed by reverse transcription. The products of reverse transcription were split into two multiplex PCR mixtures for amplification. PCR products from the two mixtures were combined after amplification, cleaned up, fragmented, and labeled. The labeled products were then hybridized to RPM v.1 chips. After the chips were washed and stained, the sequences generated from RPM v.1 were exported as FASTA-formatted files and further analyzed for pathogen identification using the automatic pathogen identification algorithm.
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and Streptococcus pneumoniae (10 5 to 10 1 genome copies), the results showed that RPM v.1 can detect both pathogens to a dilution of 100 genome copies of S. pneumoniae (data not shown). In similar experiments, the combinations of influenza A virus (H1N1) with S. pneumoniae and of S. pyogenes with S. pneumoniae also demonstrated that both pathogens are detected to a dilution of 100 genome copies of S. pneumoniae (data not shown).
The effectiveness of simultaneous multiple pathogen detection was also tested with more-complex mixtures. Three to seven available cultured organisms were spiked at different titers (10 2 to 10 5 CFU or PFU/ml) into pooled nasal wash samples collected from volunteers, and 150 l of the prepared samples was used for testing. Initial results revealed that this approach allowed unambiguous detection of seven pathogens-HAdV-4, HAdV-7, influenza A virus (H1N1), parainfluenza virus 1, respiratory syncytial virus A (RSV-A), M. pneumoniae, and S. pyogenes-simultaneously at the lowest titer, 100 CFU (or PFU)/ml (see Table S4A in the supplemental material). Further assessment with a set of six pathogens showed that HAdV-4, Bacillus anthracis, influenza A virus (H1N1), RSV-A, and M. pneumoniae were detected at the lowest titer tested, 100 CFU (PFU)/ml, and S. pyogenes was detected at 1,000 CFU/ml (see Table S4B in the supplemental material). For further confirmation, RPM v.1 was tested using eight cultured organisms combined to form three different sets of three pathogens (see Table S4C in the supplemental material). In all sets tested, the assay could reproducibly detect HAdV-4, M. pneumoniae, B. anthracis, influenza A virus (H1N1), human coronavirus 229E, or RSV-A at titers as low as 100 CFU (PFU)/ml and S. pyogenes to only 1,000 CFU/ml. These results indicate that the resequencing array-based approach is an effective means of detecting and typing various pathogens directly from nasal wash samples with the benefit of high sensitivity and specificity, even when as many as seven pathogens are present. Assessment of clinical specimens. After the capability of the RPM v.1 assay for pathogen detection was successfully demonstrated, it was used for prospective and retrospective diagnoses of infections causing ARI. Clinical specimens, collected primarily from military recruits presenting with ARI, were used to compare the utility of the microarraybased diagnostic to more-established methods of respiratory pathogen detection. The samples (n ϭ 101) consisted of throat swabs, in viral transport medium, from patients with clinically documented respiratory illness. Samples were chosen randomly from sets that had tested positive for HAdV or influenza virus by assays performed at NHRC, a CAP-certified molecular diagnostic laboratory (cell culture and/or PCR), but that were not tested for any other pathogen. As controls, samples that had tested negative for HAdV or influenza virus were also included for testing. These were blinded (randomly renumbered and separated from the associated clinical records) and sent to the Naval Research Laboratory for RPM v.1 testing, and the sample identities were revealed only after the results had been finalized. For pathogens detected in at least two samples each (HAdV, influenza A virus, S. pneumoniae, and M. pneumoniae) by RPM v.1, published species-specific (11, 24) or selected inhouse specific PCR primers (see Table S2 in the supplemental material) were used to perform quantitative real-time PCR for a subset of the clinical samples (limited to only 40 due to the availability of the samples) ( Table 3 ). The lack of samples makes it difficult to properly estimate the clinical sensitivity and specificity for some of the pathogens detected by RPM v.1, and so data for these pathogens, such as Neisseria meningitidis, are not reported.
For influenza A virus, the RPM v.1 method showed a detection sensitivity of 87% and a specificity of 96% with respect to the initial diagnostic result and an overall agreement of 92% (Table 4 ). For adenovirus, the RPM v.1 detection sensitivity was 97% with 97% specificity, for an overall agreement of 97% (Table 4 ). For influenza A virus, the RPM v.1 result had better agreement with culture than PCR did, which suggests that the assay has better sensitivity and specificity than PCR (Table 5) . It should be noted that three of the six false-negative and one of two false-positive clinical samples by RPM v.1 were samples that were retested by quantitative real-time PCR. The three false-negative samples also were not detected by PCR, suggesting that the samples no longer contained any detectable viral material due to possible degradation of the RNA during storage or transport. The false positive, however, was confirmed, since real-time PCR did not detect influenza A virus. In addition to detecting single pathogens in the clinical samples, the assay also detected several multiply infected samples, primarily possible coinfections. The presence of multiple pathogens was verified in a subset of 40 clinical samples by using quantitative real-time PCR. The differences in the titers of the pathogens confirmed the assay's ability to detect pathogens at similar titers and at very different titers in the same sample. It is well known that S. pneumoniae (26% of samples) and N. meningitidis (16% of samples) are commensal bacteria in the mouth and upper respiratory system, so it is not surprising that these were commonly found in clinical samples. However, quantitative real-time PCR data showed that 32% of the influenza virus-positive samples harbored titers higher than expected for S. pneumoniae (7/25) or N. meningitidis (1/25) (Ն10 4 genome copies/l) ( Table 3 ). The high titers of bacteria present in these clinical samples were possibly due to virally induced bacterial superinfection, consistent with the findings of Madhi and Klugman (20) and Peltola and McCullers (26) .
This study further demonstrated the capability of this assay to identify the subtypes of the influenza viruses and track genetic changes of the influenza virus strains in clinical samples. This is especially critical for influenza epidemiology, since antigenic drift is the mechanism by which influenza viruses escape from immunological pressure induced by previous natural exposures and vaccination. Analysis of the HA and NA sequences generated from RPM v.1 for the influenza A viruspositive clinical samples recapitulated the known lineage a CAP-approved PCR. b One of the samples testing negative by CAP-approved PCR was cultured for influenza A virus, and RPM v.1 showed HAdV-4 and influenza A coinfection. The other negative sample was confirmed to have low-titer HAdV-4.
c Three samples that were culture positive for influenza A virus could not be detected by quantitative real-time PCR as well, suggesting that the templates were degraded. (12, 33) . Two samples collected during the same period could be identified only as influenza A virus (H3N2). This was due to poor amplification and/or hybridization of targets, resulting in insufficient sequence information for strain-level identification. 
DISCUSSION
Clinical syndromes are seldom specific to single pathogens, so assays that allow testing for, and discrimination among, a large number of candidate pathogens will undoubtedly be beneficial to public health efforts (2) . The data presented here indicate that the RPM v.1 system is potentially such an assay for direct (uncultured) clinical specimens, obtaining results that will correlate well with those of conventional detection methods while providing sequence information. While earlier studies (13, 18, 39) demonstrated the usefulness of the RPM v.1 array for discriminating among 20 common respiratory and 6 biothreat pathogens, failure to meet requirements for detecting low-titer pathogens in complex clinical samples led to alteration of the amplification strategy. The use of a properly designed multiplex PCR amplification method with a resequencing array avoids some of the trade-off between specificity and sensitivity often seen in other diagnostic assays. The sensitivity of the new protocol for all pathogens, by using control samples either in extraction buffer or together as complex mixtures spiked into healthy-patient clinical samples, was on a par with that of alternate detection methods and met diagnostic requirements. Furthermore, genetically close neighbors could still be detected, as demonstrated for HAdV's, indicating that the multiplex PCR method maintained an ability for broad target enrichment. This study shows specifically that this assay exhibits the ability to resolve complex coinfections of as many as seven pathogens without a loss of sensitivity in simulated samples. The data show for clinical samples that the assay offers a sensitivity equivalent to those of accepted RT-PCR/ PCR-and culture-based methods for both HAdV and influenza A virus, using 101 throat-swab samples from patients with influenza-like illnesses. This group of samples also contained examples of coinfections that were successfully detected. While the RPM v.1 has provided confirmation of many concepts, fully establishing the clinical sensitivity and specificity of every pathogen is not worthwhile, since this particular microarray represents an incomplete coverage of respiratory pathogens and would not be ideal for real-world diagnostics or surveillance. Our ongoing efforts have focused on a new microarray that has more-complete coverage of the respiratory pathogens and for which a complete clinical validation would be worthwhile.
Commensal microflora has been viewed as a source of specimen contamination and an occasional opportunistic pathogen, but it may play a more important role in health and disease than was once thought (29) . Madhi and Klugman (20) and Peltola and McCullers (26) have reported that ϳ30% of respiratory viral infections predispose patients, both adults and children, to bacterial superinfection. These superinfections are thought to be the source of many influenza-related pneumonias and subsequent deaths (27) . It is not surprising that RPM v.1 methods detected S. pneumoniae and N. meningitidis in several clinical samples, since it is well known that both are commensal bacteria present in the upper respiratory tract. However, it is noteworthy that while most of these bacteria appeared to be present at low titers in the samples, high titers of these pathogens were regularly seen in influenza A viruspositive samples. Although the RPM v.1 assay does not determine the titers of the pathogens detected, the assay can effectively detect coinfection. This type of assay would be highly effective in studies to establish more firmly whether a clinical correlation of disease exists in cases of coinfection. If situations where this occurs are established, a diagnostic test based on a resequencing array will be valuable for the effective treatment of the primary agent and secondary coinfecting organisms, with prompt treatment using appropriate antibiotics.
Unlike traditional methods, the optimized RPM v.1 assay not only identifies pathogens but also provides sequence information, allowing a large number of pathogens to be detected and phylogenetically categorized for genetic variation analysis in the same assay (19, 39) . While the specific HA genes allowed detailed tracking of changes in a specific subtype, one M gene (H1N1) sequence that is relatively conserved among influenza A viruses tiled on the RPM v.1 was still able to detect homologous regions of disparate subtypes, allowing correct differentiation (Table 6 ). This M gene ProSeq would theoretically allow detection of any other type of influenza virus for which specific antigenic HA and NA sequences were not tiled on the array. In the future, this method of mixing specific and conserved targeting will be useful for enhancing clinical management and epidemic outbreak responses by permitting accurate fingerprinting, antibiotic resistance profiling, genetic drift/shift analysis, forensics, and many other parameters of important pathogens while maintaining coverage of a large number of pathogens. This capability will be invaluable for rapid detection of emerging diseases, such as avian influenza virus (H5N1), and biological terrorism events. In addition, with the capability for simultaneous resequencing of dozens of gene targets from multiple pathogens in a single assay, the technology is an excellent tool for identifying minor variants within a population that may emerge and become dominant when selection pressure changes, without the need to isolate before proceeding with the sequencing reaction.
While the RPM v.1 chips with multiplex amplification demonstrated remarkable diagnostic and surveillance capabilities, the following factors must be taken into account before introducing this technique in the diagnostic laboratory. One major hurdle that limits the use of a resequencing array to broadspectrum pathogen diagnostics has been the selection of the primers for amplification of chosen target species and near neighbors prior to microarray hybridization. In this study, we showed that multiplex PCR can reach the desired clinical sensitivity and detect the presence of close genetic neighbors; however, the current system remains somewhat vulnerable to the rapid mutation of the RNA virus, and each new resequencing array design would require recalibrating the mix of multiplex primers. Future work will attempt to simplify the redesign method and also try to find alternative amplification methods that provide the necessary sensitivity with more-comprehensive coverage.
Another issue, in the current array format, is that a limited number of probe sets can be placed on the microarray, and so very detailed information cannot be obtained for every pathogen. Currently the targets must be carefully chosen, or the microarray will not provide the coverage or detailed information desired. As the number of probe sets that can be placed on the microarray continues to increase, the trade-off between specific and conserved targets in the effort to provide sufficient detailed information while maintaining coverage will become less of an issue. Indeed, our newer chip design has improved upon the content of the detectable pathogens, which will further broaden the detection capability of the resequencing array.
In its current format, this assay can be performed at centralized laboratories in 8.5 h with a completely automated pathogen identification process. However, this is not suitable for a point-of-care diagnostic tool. The simplicity of the assay should allow it to be adapted to a fully automated process, increasing throughput, further decreasing the assay time, and reducing the error rate caused by human handling. With these alterations, it should be possible to implement this assay as a pointof-care analysis system. The cost of this assay compared to that of rapid single assays is high, although factoring the cost of all the rapid assays required to give the same information indicates that the relative cost difference for the two methods is not as significant. Considering costs on a per-test basis, the advancements occurring in microarray production technology should provide even higher density microarrays with a reduced chip cost, and steps taken to produce a point-of-care system would also result in a reduction in the overall assay cost, which leads us to believe that newer-generation chips providing more-comprehensive coverage will be cost-effective in the near future. The benefits of this approach, with clear paths to overcome or reduce its limitations, make this an attractive assay method to develop for detecting respiratory pathogens. Future development will include addressing the most important limitations: designing a new resequencing array with more-comprehensive coverage of respiratory pathogens, improving primer selection, and integrating microarrays and microfluidics into a portable device, allowing the possibility of transferring this reference lab method into the point-of-care field.
